Comparing New and Existing GLP-1 Medications

Photo by Haberdoedas Photography via Pexels

Quick Answer

Comparing new and existing GLP-1 medications reveals significant advancements in weight management and diabetes care. Newer options like tirzepatide show enhanced efficacy and broader benefits. Understanding these differences helps tailor treatments to individual needs.

GLP-1 receptor agonists have revolutionized the management of type 2 diabetes and obesity. With new medications entering the market, it's crucial to understand how they compare with existing options. This comprehensive guide will explore the current GLP-1 medications, introduce new contenders, and analyze their effectiveness and safety profiles.

What Are the Current GLP-1 Options on the Market?

GLP-1 receptor agonists work by mimicking the incretin hormone, which increases insulin secretion, slows gastric emptying, and decreases appetite. These effects make them pivotal in managing type 2 diabetes and promoting weight loss. Let's look at the main players currently available.

Semaglutide

Semaglutide, available under brand names like Ozempic and Wegovy, is one of the most prescribed GLP-1 medications. It is administered weekly and has shown remarkable efficacy in both glycemic control and weight management. Clinical trials like the STEP 1 trial reported an average weight loss of 14.9% over 68 weeks^[1]. This impressive weight reduction is attributed to semaglutide's strong appetite-suppressing effects and its ability to slow gastric emptying significantly.

Dulaglutide

Dulaglutide, marketed as Trulicity, is another weekly GLP-1 option. It is primarily used for type 2 diabetes management. In the head-to-head AWARD-6 trial, dulaglutide 1.5 mg lowered HbA1c by 1.42 percentage points over 26 weeks, similar to daily liraglutide 1.8 mg (1.36 points)^[2]. However, its weight loss effects are generally less pronounced than semaglutide's: in the SUSTAIN 7 trial, people taking dulaglutide 1.5 mg lost an average of 3.0 kg (about 6.6 lb) over 40 weeks, compared with 6.5 kg on semaglutide 1 mg^[3]. Dulaglutide's efficacy in glucose control makes it an appealing choice for patients prioritizing HbA1c reduction over weight loss.

Liraglutide

Liraglutide, known by the brand name Victoza for diabetes and Saxenda for weight loss, is a daily injectable GLP-1. It has been in use for several years and is well-documented for both glucose control and weight reduction. In the 56-week SCALE trial of adults without diabetes, liraglutide 3.0 mg (the Saxenda dose) led to an average loss of 8.4 kg (about 18.5 lb), compared with 2.8 kg on placebo^[4]. Its daily administration can be a drawback for some, but its dual approval for both diabetes and obesity provides flexibility in treatment.

Exenatide

Exenatide is available in two formulations: Byetta (twice daily) and Bydureon (weekly). It was one of the first GLP-1 medications introduced and is effective in glucose regulation. In the 30-week DURATION-1 trial, the once-weekly form lowered HbA1c more than the twice-daily form (1.9 vs 1.5 percentage points), with similar reductions in body weight^[5]. Twice-daily exenatide's shorter half-life necessitates more frequent dosing but offers a rapid onset of action, which can be beneficial in certain clinical scenarios.

What Are the New GLP-1 Medications Launching?

The GLP-1 landscape is rapidly evolving with the introduction of new medications promising enhanced benefits. Let's explore these new entrants and what they bring to the table.

Tirzepatide

Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual-acting GLP-1 and GIP receptor agonist. This novel mechanism enhances insulin secretion and offers superior weight loss outcomes. In the SURMOUNT-1 trial of adults with obesity, tirzepatide led to an average weight loss of 20.9% over 72 weeks at the highest dose of 15 mg^[7]. This dual action is a game-changer for both diabetes and obesity treatment, providing a more holistic approach to metabolic health.

Retatrutide

Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. In a 48-week phase 2 trial of 338 adults with obesity or overweight, the 12 mg dose lowered body weight by an average of 24.2%, compared with 2.1% on placebo^[10]. Phase 3 trials have since begun reporting results, but as of October 2026, retatrutide is not FDA-approved.

Cagrilintide

Cagrilintide is an amylin analogue studied in combination with semaglutide 2.4 mg (a combination known as CagriSema). In the 68-week phase 3a REDEFINE 1 trial of adults with overweight or obesity who did not have diabetes, the combination lowered body weight by an average of 20.4%, compared with 3.0% on placebo, in an analysis that counted all participants whether or not they stayed on treatment^[11]. As of October 2026, CagriSema is not FDA-approved; Novo Nordisk has submitted it to the FDA for review.

How Do New GLP-1 Medications Compare in Effectiveness and Safety?

Understanding the differences in effectiveness and safety between new and existing GLP-1 medications is essential for making informed treatment decisions.

Effectiveness

• Weight Loss: Newer medications like tirzepatide offer significantly higher weight loss outcomes compared to existing options. For instance, in separate trials (not head-to-head), tirzepatide 15 mg produced an average 20.9% weight loss over 72 weeks in SURMOUNT-1^[7], while semaglutide 2.4 mg produced 14.9% over 68 weeks in STEP 1^[1]. In the head-to-head SURPASS-2 trial in people with type 2 diabetes, all tirzepatide doses lowered body weight more than semaglutide 1 mg^[6]. This greater weight loss may be partly due to tirzepatide's dual-receptor activity.
• Glycemic Control: Both new and existing GLP-1 medications are effective in reducing HbA1c levels. However, in the head-to-head SURPASS-2 trial, all three tirzepatide doses lowered HbA1c more than semaglutide 1 mg over 40 weeks^[6]. Tirzepatide's action on both GLP-1 and GIP receptors may contribute to this difference.

Safety Profile

• Common Side Effects: Nausea, vomiting, and diarrhea are common side effects across all GLP-1 medications. In the SURPASS-2 trial, nausea was reported by 17% to 22% of patients taking tirzepatide and 18% taking semaglutide 1 mg^[6]. These side effects are usually transient and can be managed by gradual dose escalation.
• Long-term Safety: New medications like tirzepatide are still undergoing long-term safety evaluations. Existing medications like semaglutide have a longer track record, and semaglutide's prescribing information warns of rare but serious risks such as acute pancreatitis, along with a boxed warning about thyroid C-cell tumors seen in rodent studies^[8]. Ongoing surveillance of newer medications continues to look for emerging safety concerns.

Comparison Table

Frequently Asked Questions

What are the benefits of newer GLP-1 medications?

Newer GLP-1 medications like tirzepatide offer superior weight loss and glycemic control due to their dual or triple receptor targeting mechanisms. They provide more comprehensive metabolic benefits compared to older GLP-1s. This is particularly beneficial for patients with both obesity and type 2 diabetes, as these medications address multiple aspects of metabolic dysfunction.

Are new GLP-1 medications safe?

New GLP-1 medications are generally safe but are still undergoing long-term safety studies. Common side effects include gastrointestinal issues, similar to existing GLP-1s. Always consult with a healthcare provider for personalized advice. The newer formulations are designed to minimize side effects while maximizing therapeutic benefits.

How do GLP-1 medications aid in weight loss?

GLP-1 medications promote weight loss by slowing gastric emptying, reducing appetite, and increasing insulin secretion. This combination leads to reduced calorie intake and improved metabolic health. For instance, by delaying gastric emptying, these medications increase the feeling of fullness after meals, reducing overall food consumption.

Can I switch from an existing GLP-1 to a new one?

Switching between GLP-1 medications should be done under medical supervision. Factors like individual response, side effects, and specific health goals should be considered when deciding to switch. A healthcare provider can help evaluate the potential benefits and risks of switching, ensuring the transition is smooth and effective.

What should I consider when choosing a GLP-1 medication?

Consider factors like weight loss goals, diabetes management needs, dosing frequency, and potential side effects. Consulting with a healthcare provider can help tailor the choice to your specific health profile. It's also important to consider lifestyle factors, such as the convenience of dosing frequency and personal preferences.

What is the impact of GLP-1 medications on cardiovascular health?

GLP-1 medications have shown favorable effects on cardiovascular health, including reduced risk of major adverse cardiovascular events. For example, the LEADER trial demonstrated that liraglutide reduced the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes^[9]. This makes them an attractive option for patients with cardiovascular risk factors.

Sources and References

[1] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

[2] Dungan KM, et al. "Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial." Lancet. 2014;384(9951):1349-1357. https://pubmed.ncbi.nlm.nih.gov/25018121/

[3] Pratley RE, et al. "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial." Lancet Diabetes Endocrinol. 2018;6(4):275-286. https://pubmed.ncbi.nlm.nih.gov/29397376/

[4] Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." N Engl J Med. 2015;373(1):11-22. https://pubmed.ncbi.nlm.nih.gov/26132939/

[5] Drucker DJ, et al. "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study." Lancet. 2008;372(9645):1240-1250. https://pubmed.ncbi.nlm.nih.gov/18782641/

[6] Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/

[7] Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[8] U.S. Food and Drug Administration. "Ozempic (semaglutide) Prescribing Information." DailyMed. dailymed.nlm.nih.gov

[9] Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." N Engl J Med. 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/

[10] Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972

[11] Garvey WT, Blüher M, Osorto Contreras CK, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2025;393(7):635-647. https://doi.org/10.1056/NEJMoa2502081

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for advice about treatments and medications.